62nd ASH Annual Meeting and Exposition: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III

Oral and Poster Abstracts
Poster

Adult, ALL, antibodies, Biological, Coronaviruses, Leukemia, multiple myeloma, SARS-CoV-2/COVID-19, viral, bacterial, CLL, Diseases, Non-Biological, Combinations, Therapies, Adverse Events, Non-Hodgkin Lymphoma, Pediatric, B-Cell Lymphoma, DLBCL, enzyme inhibitors, white blood cells, T-Cell Lymphoma, Technology and Procedures, Cell Lineage, Infectious Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, Quality Improvement , NGS

3417

Healthcare Resource Utilization and Sickness Absence in Newly Diagnosed Multiple Myeloma Patients in Sweden: Trends in a Changing Treatment Landscape

Fredrik Borgsten, MD¹^*, Xenia Gatopoulou, MBA²^*, Marta Pisini, MBA³^*, Magnus Tambour, PhD⁴^*, Frida Schain, PhD^5,6^*, Christina V Jones, PhD^5,7^*, Kelvin Ho Man Kwok, PhD^5,8^*, Catharina Hjortsberg, PhD⁴^* and Magnus Björkholm, MD, PhD⁶

¹Janssen-Cilag A/S, Birkerød, Denmark
²Janssen Pharmaceutical S.A.C.I., Athens, Greece
³Janssen Pharmaceutica NV, Beerse, Belgium
⁴Janssen-Cilag, Solna, Sweden
⁵Schain Research, Bromma, Sweden
⁶Department of Medicine, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden
⁷Department of Cell and Molecular Biology, Karolinska Institutet, Solna, Sweden
⁸Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden

3418

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD¹, Nicholas Liu, PharmD²^*, Kristina Yu-Isenberg, PhD, MPH, RPh²^*, Michelle A. Fanale, MD², Andy Surinach, MPH³^*, Carlos Flores, MPH³^*, Julie Lisano, PharmD²^* and Tycel J. Phillips, MD⁴

¹US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO
²Seattle Genetics, Bothell, WA
³Genesis Research, Hoboken, NJ
⁴Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI

3419

Economic Evaluation of Daratumumab and Pomalidomide and Dexamethasone Versus Isatuximab and Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Neda Alrawashdh, PharmD¹^*, Abdulaali Almutairi²^*, Ali McBride, PharmD, MS^3,4 and Ivo Abraham, PhD, RN⁵

¹Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, TUCSON, AZ
²University of Arizona, TUCSON, AZ
³University of Arizona Cancer Center, Tucson, AZ
⁴Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
⁵Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

3420

Financial Toxicity and Impact on Health-Related Quality of Life in Patients with Plasma Cell Disorders

Rahma M Warsame, MD¹, Angela Dispenzieri, MD¹ and Amylou C. Dueck, PhD²

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Health Sciences Research, Mayo Clinic, Scottsdale, AZ

3421

Intensity of End of Life Care for Hematologic Malignancy Patients in Western Washington, United States and Alberta, Canada

Ali Raza Khaki, MD¹, Yuan Xu, PhD²^*, Shasank R Chennupati, PharmD, MPH³^*, Scott D Ramsey, MD, PhD⁴^*, Catherine Fedorenko, MMSci⁴^*, Veena Shankaran, MD^4,5^*, Winson Y Cheung, MD MPH⁶^* and Andrew J. Cowan, M.D.^7,8

¹Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
²Alberta Health Services, Calgary, AB, Canada
³Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Fred Hutchinson Cancer Research Center, Seattle, WA
⁵Medicine, University of Washington, Seattle, WA
⁶Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
⁷Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Division of Medical Oncology, University of Washington, Seattle, WA

3422

Conversion to Biosimilar Pegfilgrastim-Jmdb from Pegfilgrastim with on-Body Injector Device in Diffuse Large B-Cell Lymphoma: Simulation Modeling of Cost-Savings and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy Considering Device Failure Rate

Ali McBride, PharmD, MS^1,2,3, Karen MacDonald, PhD⁴^* and Ivo Abraham, PhD, RN^2,4,5,6,7

¹Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
²Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ
³Banner University Medical Center, Tucson, AZ
⁴Matrix45, Tucson, AZ
⁵University of Arizona Cancer Center, Tucson, AZ
⁶Department of Family and Community Medicine, The University of Arizona College of Medicine, Tucson, AZ
⁷Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

3423

Association between Spending in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma Using 2012–2017 Medicare Data

Ruben Niesvizky, MD¹, Zoe Clancy²^*, Ronda Copher, PhD²^*, Ryan B. Thomas, MD², Cynthia Z. Qi, MBA³^*, Zheng-Yi Zhou³^*, Miriam L. Zichlin⁴^*, Sarah H. Koenigsberg³^* and James E. Signorovitch³^*

¹NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY
²Bristol Myers Squibb, Princeton, NJ
³Analysis Group Inc., Boston, MA
⁴Analysis Group, Inc., Boston, MA

3424

Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Ming-Hui Tai, PhD¹^*, Eric M. Ammann, PhD¹^*, Shuchita Kaila, PhD¹^*, Christopher Pericone¹^*, Ajaybir Singh²^*, Thomas S. Lin, MD, PhD¹ and Faith E. Davies³

¹Janssen Scientific Affairs, Horsham, PA
²Mu Sigma, Bengaluru, India
³Perlmutter Cancer Center, New York University Langone Health, New York, NY

3425

Simulation Modeling of Cost-Savings from Conversion to Biosimilar Pegfilgrastim-Cbqv for the Prophylaxis of Chemotherapy-Induced Neutropenia, and Budget-Neutral Expanded Access to Prophylaxis and Anti-Neoplastic Therapy from Derived Cost-Savings in Non-Hodgkin Lymphoma

Ali McBride, PharmD, MS^1,2,3, Karen MacDonald, PhD⁴^* and Ivo Abraham, PhD, RN^2,4,5,6,7

¹Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
²Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ
³Banner University Medical Center, Tucson, AZ
⁴Matrix45, Tucson, AZ
⁵University of Arizona Cancer Center, Tucson, AZ
⁶Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ
⁷Colleges of Pharmacy and Medicine, University of Arizona, Tucson, AZ

3426

Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma

Josh J Carlson, MPH, PhD¹^*, Marita Zimmermann, MPH, PhD²^*, Audrey Demaree, PharmD³^*, Tony Hewitt³^*, Benjamin Eckert³^* and Ajay Nooka, MD, MPH⁴

¹University of Washington, Seattle, WA
²Institution for Disease Modeling, Bill and Melina Gates Foundation, Seattle, WA
³Adaptive Biotechnologies, Seattle, WA
⁴Winship Cancer Institute, Emory University, Atlanta, GA

3427

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD^1,2, Carlos Bachier, MD^2,3, Vikas Bhushan, MD^2,4^*, Michael J. Eckrich, MD, MPH^2,5, Alireza Eghtedar, MD^2,6^*, Haydar Frangoul, MD^2,7^*, Suman Kambhampati, MD^2,8^*, Shahbaz Malik, MD^2,9^*, Peter A. McSweeney, MD^2,6^*, Jeremy Pantin, MBBS^2,3, Aravind Ramakrishnan, MD^2,9, Hana Safah, MD^2,10, Paul J Shaughnessy, MD^2,11, Betsy Blunk, BSN, RN, BMTCN²^*, Tonya Cox, BSN, RN², Rocky Billups, MS² and Charles F. Lemaistre, MD²

¹Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center, Nashville, TN
²Sarah Cannon Blood Cancer Network, Nashville, TN
³Sarah Cannon Center for Blood Cancer at Tristar Centennial Medical Center, Nashville, TN
⁴Texas Oncology at Medical City Dallas, Dallas, TX
⁵Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX
⁶Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
⁷Sarah Cannon Cancer Center at Tristar Centennial Medical Center, Nashville, TN
⁸Sarah Cannon Blood Cancer Center at Research Medical Center, Kansas City, MO
⁹Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
¹⁰Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA
¹¹Texas Transplant Institute at Methodist Hospital, San Antonio, TX

3428

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Matthew C. Cheung, MD, MSc¹, Nicole Mittmann, PhD²^*, Carolyn Owen, MD FRCPC³, Nizar Abdel-Samad, MD⁴, Graeme Fraser⁵, Selay Lam, MD, BSc, FRCPC⁶, Michael Crump, MD⁷, Catherine Sperlich⁸^*, Richard van der Jagt⁹, Stephen Couban, MD, BSc¹⁰, Jennifer A. Woyach, MD¹¹, Amy S. Ruppert, PhD¹², Allison M Booth¹³^*, Sumithra J Mandrekar, PhD¹³^*, Gail T. McDonald¹⁴^*, Lois E. Shepherd¹⁴, Anca Prica, MD¹⁵, Hope Yen¹⁶^*, Bingshu E. Chen¹⁴^* and Annette E. Hay¹⁷

¹Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
²Sunnybrook Research Institute, Toronto, Canada
³Foothills Hospital & Tom Baker Cancer Ctr., Calgary, AB, Canada
⁴The Moncton Hospital, Moncton, NB, CAN
⁵Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
⁶Department of Medicine, Division of Hematology, Western University, London Health Sciences Centre, London, ON, Canada
⁷Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
⁸Hopital Charles-Lemoyne, Longueuil, QC, CAN
⁹Ottawa Hospital and University of Ottawa, Ottawa, ON, Canada
¹⁰Department of Hematology, Dalhousie University, Halifax, NS, Canada
¹¹The Ohio State University Comprehensive Cancer Center, Columbus, OH
¹²Division of Hematology, The Ohio State University, Columbus, OH
¹³Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN
¹⁴Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada
¹⁵Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
¹⁶Canadian Cancer Trials Group, Kingston, ON, Canada
¹⁷Canadian Cancer Trials Group, Cancer Research Institute, Kingston, ON, Canada

3429

Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev¹^*, Allison Spinelli, MSc²^*, Elisabeth Absalon³^*, Tara Masterson, MSc⁴^*, Chris Heuck, MD⁴^*, Annette Lam, MSc²^* and Erwin De Cock, MSc³^*

¹Janssen Global Services, LLC, Raritan, NJ
²Janssen Global Services, Raritan, NJ
³Syneos Health Clinical Spain S.L., Madrid, Spain
⁴Janssen Research & Development, LLC, Spring House, PA

3430

The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL

Sarah Thompson¹^*, Tasneem Elnafie¹^*, Tatiana Elwes¹^*, Wilam Alfred¹^*, Alinane Munyenyembe¹^*, Kabir Mohammed²^*, Bhupinder Sharma, MBBS, BSc(Hons) BM FRCR¹^*, Ian Chau, MD¹^*, David Cunningham, MD, FRCP, FMedSci¹^*, Sunil Iyengar, MD, FRCPath, PhD¹^* and Dima El-Sharkawi³^*

¹The Royal Marsden NHS Foundation Trust, London, United Kingdom
²Royal Marsden Hospital, London, United Kingdom
³The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

3431

Level of Scientific Evidence Underlying Recommendations from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?

Aakash Desai, MD¹, Harry E Fuentes, MD, MS²^*, Sri Harsha Tella, MD²^*, Caleb J Scheckel, DO³, Thejaswi Poonacha, MD⁴^* and Ronald S. Go, MD⁵

¹Division of Hematology, Department of Medicine, MayoClinic, Rochester, MN
²Division of Hematology, Department of Medicine, MayoClinic, Rochester
³Division of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, AZ
⁴Department of Medicine, University of Minnesota, Minneapolis
⁵Division of Hematology, Mayo Clinic, Rochester, MN

3432

Infectious Outcomes of Pediatric Acute Lymphoblastic Leukemia Patients Presenting with Non-Neutropenic Fever

Pratik A. Patel, MD¹^*, Nicholas P. DeGroote, MPH²^*, Adam J. Esbenshade, MD, MSc³^*, William T. Cash, MD, MSc¹^*, Sharon M. Castellino, MD, MSc⁴, Preeti Jaggi, MD⁵^* and Tamara P. Miller, MD, MSc¹

¹Aflac Cancer and Blood Disorders Center, Emory University School of Medicine/Children's Healthcare of Atlanta, Atlanta, GA
²Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
³Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN
⁴Aflac Cancer and Blood Disorders Center, Emory University School of Medicine / Children's Healthcare of Atlanta, Atlanta, GA
⁵Department of Pediatric Infectious Disease, Emory University School of Medicine/Children’s Healthcare of Atlanta, Atlanta, GA

3433

Adoption of Approved CAR-T Therapies Among US Community Hematologists/ Oncologists

Ajeet Gajra, MD, MBBS, Skyler Hime^*, Yolaine Jeune-Smith, PhD^* and Bruce Feinberg, DO

Cardinal Health Specialty Solutions, Dublin, OH

3434

Prospective Pilot Study of Telehealth As Domiciliary Follow-up after Hematopoietic Cell Transplantation during the COVID19 Pandemic

Alberto Mussetti, MD¹^*, Maria Queralt Salas Gay, MD²^*, Maria Condom, MD³^*, Maite Antonio, MD, PhD⁴^*, Cristian Ochoa⁵^*, Iulia Ivan⁶^*, David Jiménez Ruiz De La Torre, MD²^*, Gabriela Isabel Sanz-Linares, MD⁷^*, Belen Ansoleaga⁷^*, Rocio Parody, MD⁸^*, Ali Bazarbachi, MD, PhD⁹ and Anna Sureda Balari, MD, PhD^10,11^*

¹Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet De Llobregat, Barcelona, Spain
²Hematology, Institut Catalá d'Oncologia, L'Hospitalet de Llobregat, Spain
³Hematology Department, Institut Catala d'Oncologia, Hospital Duran i Reynals. IDIBELL, Hospitalet de Llobregat, Spain
⁴Oncohematogeriatrics Unit, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, L'Hospitalet De Llobregat, Barcelona, Spain
⁵Psycho-Oncology Unit and ICOnnecta’t Health Program, Institu Catalá d'Oncologia, L’Hospitalet de Llobregat, Spain
⁶Hematology, Institut Catalá d'Oncologia, Hospitalet de Llobregat, Spain
⁷Institut Catalá d'Oncologia, Hospitalet de Llobregat, Spain
⁸ICO-Hospital Duran i Reynals, Barcelona, Spain
⁹Department of Hematology and bone marrow transplant, American University of Beyrouth, Beyrouth, Lebanon
¹⁰Clinical Hematology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain
¹¹ICO-Hospital Duran i Reynals, Hospitalet del Llobregat, Spain

3435

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Stephanie Boisclair, MD¹, Richie Uba, PharmD²^*, Amanda Brahim, PharmD³^*, Fernando Vargas Madueno, MD⁴^*, Julio C. Chavez, MD⁵ and Jose Sandoval-Sus, MD⁴

¹Internal Medicine Residency, Memorial Healthcare System, Pembroke Pines, FL
²Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Davie, FL
³Department of Pharmacy, Memorial Hospital West, Pembroke Pines, FL
⁴Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, Moffitt Cancer Center, Pembroke Pines, FL
⁵Division of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Lutz, FL

3436

Predictors of Healthcare Utilization in Newly Diagnosed Myeloma

Shane Toolan, MRCP¹^*, Mark Griffin, MB BCh BAO²^*, Mark Coyne³^*, Kate O'Mahony, BSc Pharm²^*, Joy Lewis³^*, Chandan D'Souza⁴^*, Daniel G Connaghan, MD⁵, Karen Murphy, MD³, Kamal Fadalla, FRCPath⁵^*, Joan Marie Fitzgerald, BSc, FRCPath, MBBChir³^*, Conor Collins⁵^*, Niall Swan, MRCP, MB⁶^*, Crotty Tom³^*, Gibbons David³^* and Liam Smyth, MD, FRCPath⁵

¹Department of Haematology, St. VIncent's University Hospital, Dublin, Ireland
²Department of Haematology, St. Vincent's University Hospital, Dublin, Ireland
³St. Vincent's University Hospital, Dublin, Ireland
⁴Department of Haematology, St. Vincent's University Hospital, Dublin 4, Ireland
⁵St Vincent's University Hospital, Dublin, Ireland
⁶St. Vincent's University Hospital, Dublin, IRL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH